公开(公告)号：US20210238305A1

公开(公告)日：2021-08-05

申请号：US17049768

申请日：2020-02-25

Applicant: REMEGEN CO., LTD.

Inventor： Zhanjiao YU ,  Yuanhao LI ,  Changjiang HUANG ,  Wang LIANG ,  Haiyan MAO ,  Jianmin FANG

IPC: C07K16/32 ,  G01N33/574 ,  G01N33/68

Abstract: The invention provides an antibody for human epidermal growth factor receptor 2 (Her2) concomitant diagnostic immunohistochemical detection (IHC). When the antibody is used as a primary antibody for immunohistochemical detection of Her2 expression, false positives in detection results caused by the absence of an extracellular region can be avoided. Moreover, the antibody can still recognize and bind to the corresponding epitope in the detection sample when the patient's immunohistochemical detection sample is not repaired by an antigen (or epitope), thereby reducing the issue of a false negative caused by the difference in repairing methods of the antigen (or epitope) in an IHC test.

公开(公告)号：US20240165253A1

公开(公告)日：2024-05-23

申请号：US17797720

申请日：2021-08-31

Applicant: REMEGEN CO., LTD.

Inventor： Jianmin FANG ,  Changjiang HUANG ,  Xuejing YAO ,  Wenting LUO

IPC: A61K47/68 ,  A61K47/54 ,  A61P1/00 ,  A61P11/00 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K47/6849 ,  A61K47/545 ,  A61K47/6803 ,  A61K47/6817 ,  A61P1/00 ,  A61P11/00 ,  A61P35/00 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/31

Abstract: The present disclosure relates to the technical field of c-Met antibody drugs, specifically to a c-Met-targeted antibody-drug conjugate and applications thereof. The antibody-drug conjugate of the present disclosure comprises an antibody conjugated with one or more therapeutic agents or antigen-binding fragments of the antibody, is able to effectively inhibit the growth of a tumor tissue, provides a significant inhibitory effect with respect to c-Met-positive cancer, and has excellent safety.

公开(公告)号：US20240189341A1

公开(公告)日：2024-06-13

申请号：US18011194

申请日：2022-06-21

Applicant: REMEGEN CO., LTD.

Inventor： Xinling ZHANG ,  Wenting LUO ,  Yue WANG ,  Jie ZHOU ,  Qilin YIN ,  Changjiang HUANG ,  MARIE M. ZHU

IPC: A61K31/724 ,  A61K47/68 ,  A61P35/00 ,  C07K16/32

CPC classification number: A61K31/724 ,  A61K47/6877 ,  A61P35/00 ,  C07K16/32 ,  C07K2317/24

Abstract: The present disclosure provides a pharmaceutical combination and use thereof. By using an effective amount of methyl-β-cyclodextrin as a preparation component or a combined auxiliary drug, the efficacy of ADC can be significantly improved, so that some of the ADC drugs with safety issues caused by excessive dosage can be developed. Moreover, due to the reduction in the dosage of ADC drugs, the cost of production and the cost of treatment for patients have also been greatly reduced, thereby being beneficial.